ARCH Venture Fund VIII Overage, L.P.
- SEC CIK
- 0001617237
No open-market purchases or sales filed in the past year.
Current role at each company
- NMRA Neumora Therapeutics, Inc.10% Owneras of Oct 29, 2025
- CDAK Codiak BioSciences, Inc.10% Owneras of Sep 15, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists ARCH Venture Fund VIII Overage, L.P. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
NMRA Neumora Therapeutics, Inc.
10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 29, 2025 (view filing)7:19 PM ET | Oct 27 | 2 days | ARCH Venture Fund VII, L.P. and 9 others10% Owner | PPurchase | +1.92M | $2.61 | +$5.00M | +46.4%6.05M after | Duplicate filing |
| Sep 20, 2023 (view filing)6:15 AM ET | Sep 19 | 1 day | ARCH Venture Fund VII, L.P. and 9 others10% Owner | PPurchase | +1.50M | $17.00 | +$25.5M | +70.6%3.62M after | Duplicate filing |
CDAK Codiak BioSciences, Inc.
10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2022 (view filing)6:53 PM ET | Sep 13 | 2 days | Crandell Keith and 6 others10% Owner | PPurchaseCommon Sotck | +5.00M | $1.50 | +$7.50M | +129.7%8.85M after | |
| Sep 15, 2022 (view filing)6:53 PM ET | Sep 13 | 2 days | Crandell Keith and 6 others10% Owner | PPurchase | +5.00M | – | – | –5.00M after | DerivativeDuplicate filing |